期刊文献+

肝细胞癌肝动脉化疗栓塞术后胆汁瘤形成的危险因素及临床特点分析 被引量:16

Clinical features and risk factors of biloma formation after transcatheter arterial
原文传递
导出
摘要 目的探讨肝细胞癌(HCC)肝动脉化疗栓塞(TACE)术后胆汁瘤形成的危险因素、治疗及预后。方法回顾性分析2011年1月至2013年12月在中山大学附属第三医院行TACE治疗的HCC患者481例,分析胆汁瘤发生的危险因素、临床特点、治疗及预后。结果术前合并胆道扩张、肝切除史、非超选择性插管和使用聚乙烯醇(PVA)颗粒是TACE术后胆汁瘤发生的危险因素。其中43例(8.9%)发生胆汁瘤,9例(1.9%)为有症状胆汁瘤,均进行了经皮穿刺胆汁瘤置管引流,其中7例缩小,2例消失;35例(7.3%)为无症状胆汁瘤,均进行了随访观察,其中24例无变化,8例缩小,2例消失,1例胆汁瘤明显增大,破入腹腔形成胆汁性腹膜炎,死于肝功能衰竭、感染性休克。结论合并胆道扩张、有肝切除史、术中使用PVA颗粒、非超选择性插管是肝癌TACE术后胆汁瘤形成的危险因素。有症状胆汁瘤,应及时经皮穿刺置管引流,预后良好;无症状胆汁瘤,需定期影像学随访,对于明显增大者,应及时经皮穿刺置管引流。 Objective To explore the risk factors, treatment and outcomes of biloma after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Methods A total of 481 patients with a diagnosis of HCC underwent TACE at our hospital from January 2011 to December 2013. Biloma was tracked by the follow-ups of computed tomography or magnetic resonance imaging ( CT/ MRI). Retrospective analyses were conducted for their clinical features, treatments and prognosis. The statistically significant factors for univariate analysis were introduced into Logistic regression models for muhivariate analysis to obtain the risk factors of biloma post-TACE. Results There were 43 eases of complicated biloma after TACE. And 38 patients (88.4%) developed biloma at 0. 5 -3 months post-TACE while another 5 (9.7%) did so at 3 -5 months. The multivariate analysis showed that bile duct dilation, a history of hepatectomy prior to TACE, use of polyvinyl alcohol ( PVA ) particles and nonsuperselective embolization were the risk factors of biloma formation after TACE. Among 9 symptomatics, there were jaundice ( n = 2 ) and fever ( n = 7 ). The diameter of bilomas was ( 8. 07 + 3.53 ) cm for 9 symptomaties and (2. 81 + 1.26 ) cm for 35 asymptomatics. And the difference was statistically significant (P 〈 0.01 ). Nine symptomatic patients underwent percutaneous drainage with tube and biloma diminished ( n = 7 ) and even vanished ( n = 2). Only conservative treatment was offered for 35 asymptomatics. During the follow-ups, it showed no change ( n = 24 ), diminishing ( n = 8 ) and disappearance ( n = 2 ). One case died from a greatly enlarged biloma due to hepatic failure and septic shock via a rupture into abdominal cavity and choleperitonitis. Conclusion The risk factors of biloma formation after TACE for HCC are bile duct dilation, a history of hepatectomy before TACE, use of PVA particles and nonsuperselective embolization. For symptomaties, drainage must be performed timely and the prognosis is fair. For asymptomaties, regular imaging follow-ups are needed. Drainage must be performed timely when the diameter of biloma increased significantly during the follow-ups.
出处 《中华医学杂志》 CAS CSCD 北大核心 2015年第13期1002-1005,共4页 National Medical Journal of China
基金 国家自然科学基金面上项目(81371655) 广州市科技计划项目(2013J4100118)
关键词 肝肿瘤 栓塞 治疗性 胆汁瘤 Liver neoplasms Embolization,therapeutic Biloma
  • 相关文献

参考文献10

  • 1Dai QS, Gu HL, Ye S, et al. Transarterial chemoembolization vs conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study [ J ]. Mol Clin Once,l, 2014, 2(.6):1047-1054.
  • 2王茂强,唐文捷,林汉英,叶慧义,戴光海,王志强.经导管肝动脉化疗栓塞术后胆管损伤的临床意义[J].介入放射学杂志,2005,14(5):493-497. 被引量:24
  • 3Atassi B, Bangash AK, l/ewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres [ J]. J Vase [nlerv Radiol, 2008, 19 (5) : 691-697.
  • 4Sakamoto I, Iwanaga S, Nagaoki K, et al. Intrahepatic biloma formation (bile duet necrosis ) 'after transcatheter ',arterial chemoembolization [J]. AJR Am J Roentgenol, 2003,181 ( I ) : 79-87.
  • 5Sherman M, Bruix J, Porayko M, et al. Screening for hepatoeellular carcinoma: the ratimlale for the American Association for the Study of l.iver Diseases recommendations [ J ]. Hepatology, 2012, 56(3):793-796.
  • 6Eurnpean Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL- EORTC clinical practice guidelines: management of hepatoeellular carcinoma [J]. J Hepatol, 2012, 56 (4) : 908-943.
  • 7Bhagat N, Reyes DK, l,in M, et al. Phase 11 study of chenoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury [ J ]. Cardiovasc lntervent Radinl, 2013, 36 (2) :449-459.
  • 8Pulilano C, Parks RW, Ireland H, el at. Impact of concomitant arterial injury on the outcome of laparoscopic bile duct injury [ J ]. Am J Surg, 2011,201 (2) :238-244.
  • 9陈俊伟,朱康顺,孟晓春,何可可,钱结胜,沈敏,黄文薮,单鸿.聚乙烯醇颗粒在原发性肝癌经导管肝动脉化疗栓塞术中的应用[J].中国医学影像技术,2010,26(3):559-562. 被引量:9
  • 10Pende V, Marchese M, Mutignani M, et al. Endoscopic management of biliopleural fistula and biloma after percutaneous radiofrequency ablation of liver metastasis [ J ]. Gastroin|est Endosc, 2007, 66 ( 3 ) :616-618.

二级参考文献20

  • 1陈晓明,罗鹏飞.肝癌经导管肝动脉化疗性栓塞存在的问题与对策[J].实用医学杂志,2007,23(6):786-787. 被引量:14
  • 2Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 2008,100(10):698-711.
  • 3Coldwell DM, Stokes KR, Yakes WF, et al. Embolotherapy: agents, clinical applications, and techniques. Radiographics, 1994,14(3) :623-643.
  • 4Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative combined, neoadjuvant, bridging, and symptomatic indications Eur J Radiol, 2009,72(3) :505-516.
  • 5Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol, 2003,26 (2) : 111-117.
  • 6Yu SC, Hui JW, Hui EP, et al. Embolization efficacy and treatment effectiveness of transarterial therapy for unresectable hepato cellular carcinoma: a case-controlled comparison of transarterial ethanol ablation with liplodol ethanol mixture versus transcatheter arterial chemoembolization. J Vasc Interv Radiol, 2009, 20 (3) : 352-359.
  • 7Paye F, Farges O, Dahmane M, et al. Cytolysis following chemoembolization for hepatocellular carcinomas. Br J Surg, 1999, 86(2) : 176-180.
  • 8Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology, 2003, 50:183-187.
  • 9Caturelli E, Siena DA, Fusilli S,et al.Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology, 2000, 215:123-128.
  • 10Sakamoto I, Iwanaga S, Nagaoki K,et al. Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR Am J Rentgenol, 2003, 181:79-87.

共引文献31

同被引文献143

引证文献16

二级引证文献135

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部